(Q44233639)

1 December 2017

title

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis (English)

1 reference

Mycobacterium tuberculosis

1 December 2017

main subject

0 references

1 reference

1 reference

1 reference

J C Rodríguez

1

1 reference

1 December 2017

M Ruiz

series ordinal

2

1 reference

1 December 2017

M López

series ordinal

3

1 reference

1 December 2017

G Royo

series ordinal

4

1 reference

1 December 2017

publication date

1 December 2002

1 reference

International Journal of Antimicrobial Agents

1 December 2017

published in

1 reference

1 December 2017

volume

20

1 reference

1 December 2017

issue

6

1 reference

1 December 2017

page(s)

464-467

1 reference

Mycobacteriosis and HIV infection: the new public health challenge

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Tuberculosis at the end of the twentieth century

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Tuberculosis in the AIDS era

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Drug-resistant and multidrug-resistant tubercle bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Prospective study of drug-resistant tuberculosis in a Spanish urban population including patients at risk for HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Establishment of a European network for the surveillance of Mycobacterium tuberculosis, MRSA and penicillin-resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Newly documented antimicrobial activity of quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Activity of quinolones against mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

The clinical use of fluoroquinolones for the treatment of mycobacterial diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

[Mycobacterium tuberculosis: evolution of resistance in our environment]

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Molecular epidemiology of tuberculosis in Elche, Spain: a 7-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Prolonged ciprofloxacin therapy fails to prevent reactivation tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Activity of moxifloxacin against mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Activities of linezolid against rapidly growing mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900239-X

7 January 2021

10.1016/S0924-8579(02)00239-X

Identifiers

DOI

1 reference

1 December 2017

1 reference